What is Vesugen?
Vesugen, also transliterated Vezugen, is the synthetic tripeptide Lys-Glu-Asp (KED). It belongs to the short-peptide bioregulator family and is associated with vascular endothelium, the cells lining blood vessels.[1][15]
Endothelial cells help regulate blood-vessel tone, communication and responses to injury. Vesugen research asks whether KED can alter those maintenance signals as cells age or become stressed.[15]
Purified KED, oral capsules and lingual drops are different preparations. A shared Vesugen name does not establish the same ingredients, absorbed amount or effect across them.[27]
What Vesugen is investigated for
Vesugen evidence is grouped by practical use case and oral and intraperitoneal route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.
Lower-limb blood flow
Oral
Lower-limb blood flow
Oral
Preliminary blood-flow changes need controlled confirmation alongside walking symptoms and daily function.[1]
Vascular erectile function
Oral
Vascular erectile function
Oral
Reliable improvements in erectile function remain unestablished.[2]
Evidence snapshot
Overall confidence
Preliminary findings support interest in vascular function. Confidence in symptom benefits and long-term treatment effects remains limited.[1][2][15]
Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.
Human evidence
Human findings suggest possible blood-flow improvements, with uncertain effects on symptoms and daily function.[1][2]
Animal / preclinical
In-vitro work has examined regulatory peptide effects on vascular and endothelial models; these findings do not prove clinical benefit.[1][2][3][4][5][6][7]
Mechanism support
KED may affect endothelin-1, which influences vessel narrowing, and proteins involved in cell communication and maintenance. These signals provide a rationale for interest in endothelial function.[15]
Forms & administration
Vesugen has oral capsules and lingual drops, with product-specific strengths and amounts. Injectable KED preparations remain experimental and animal-only, separate from these products.[27][28][21]
Dosing & protocols
These ranges are general reference points, not personal dosing instructions.
Safety profile
The small vascular reports do not establish a reliable side-effect rate. A separate comparative aging report described oxidative-stress and blood-cell-marker changes whose clinical importance remains unclear.[1][2][3]
Regulatory status
United States
Vesugen is not an FDA-approved drug name. Availability of a supplement or research preparation does not establish approval for a medical use.[29]
| Route | FDA drug approval | 503A compounding |
|---|---|---|
| Oral | Not Approved Vesugen is not an FDA-approved drug name. Availability of a supplement or research preparation does not establish approval for a medical use.[29] | Not Reviewed Compounding eligibility for this specific preparation has not been confirmed. Drug approval and compounding eligibility are separate questions. |
Oral
FDA drug approval
Not ApprovedVesugen is not an FDA-approved drug name. Availability of a supplement or research preparation does not establish approval for a medical use.[29]
503A compounding
Not ReviewedCompounding eligibility for this specific preparation has not been confirmed. Drug approval and compounding eligibility are separate questions.
International
Medicinal-product authorization outside the United States remains unconfirmed for the named preparation; status depends on the exact product and country.[29]
Sports & competition
WADA S0 prohibits pharmacological substances without governmental approval for human therapeutic use when no later section addresses them. An unapproved peptide preparation is not athlete-cleared.
How it works
KED may affect endothelin-1, which influences vessel narrowing, and proteins involved in cell communication and maintenance. These signals provide a rationale for interest in endothelial function.[15]
Proposed interactions with DNA and cellular transport pathways may help explain its activity. Absorption and exposure after oral use remain uncertain.[26][21][24]
Research gaps & open questions
What the current literature has not yet settled about Vesugen:
Independent randomized trials need to measure walking symptoms and blood flow after vascular surgery, or erectile function in vascular disease, to establish whether the reported changes exceed usual recovery.[1][2]
Absorption and product-comparison studies need to establish how much KED reaches the bloodstream after capsules or drops and whether either matches the experimental peptide.[24][27]
The oxidative-stress and blood-cell-marker findings in a small aging report need clarification and longer follow-up, so that their clinical safety meaning can be assessed.[3]
Common questions
Are Vesugen and Vezugen different peptides?
History & discovery
Vesugen research connects the short-peptide bioregulator program with vascular-cell maintenance. Later reports explored blood flow in people and KED activity in additional cell and animal models.[7][1]
Regional reports examined penile arterial flow and postoperative lower-limb ischemia. Their small, incompletely controlled designs supplied preliminary signals rather than a reliable estimate of treatment benefit.[2][1]
A KED study in an Alzheimer-model mouse strain expanded the work beyond blood vessels. A later correction addressed duplicated figures; this remains animal evidence, not an oral human memory treatment.[21][23]
32 citations
Vesugen research focuses on endothelial maintenance and blood flow. Human findings are preliminary, with uncertain effects on symptoms, daily function and long-term vascular health.[1][2][21][23][3][31][28][30]
